60 Degrees Pharmaceuticals, Inc. (SXTP)

NASDAQ: SXTP · Real-Time Price · USD

3.110

+0.150 (5.07%)

At close: Feb 27, 2026, 4:00 PM EST

2.890

-0.220 (-7.07%)

After-hours: Feb 27, 2026, 7:21 PM EST

SXTP Employees

60 Degrees Pharmaceuticals had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.

Employees

3

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

$454,982

Profits / Employee

-$2,825,188

Market Cap

4.00M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	3	0	-
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	-	-

Related Stocks

Company Name	Employees
Jaguar Health	49
HCW Biologics	36
GeoVax Labs	17
Galmed Pharmaceuticals	6
Enveric Biosciences	6
Oragenics	5
GRI Bio	4
Acurx Pharmaceuticals	4

Employee Rankings

SXTP News

26 days ago - 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership - GlobeNewsWire
6 weeks ago - 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - GlobeNewsWire
2 months ago - 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - GlobeNewsWire
2 months ago - 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 - GlobeNewsWire
3 months ago - 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine - GlobeNewsWire
3 months ago - 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results - GlobeNewsWire
4 months ago - 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - GlobeNewsWire
5 months ago - 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study - GlobeNewsWire